CLINICAL_TRIALS
trial_result
· 2009-03-12
Clinical Trial Update: An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder [Phase 3]
Summary
Phase 3 study evaluating SR58611A for Generalized anxiety disorder has completed an eight-week efficacy and safety evaluation.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Anxiety Disorders | Phase 3 | Status: COMPLETED